NYSE:HUMHumana Stock Price, Forecast & News

$394.43

-0.84 (-0.21 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$389.60

Now: $394.43▼

$397.73

50-Day Range

$291.63

MA: $361.93▼

$398.22

52-Week Range

$208.25

Now: $394.43▼

$412.70

Volume415,854 shs

Average Volume962,079 shs

Market Capitalization$52.15 billion

P/E Ratio20.25

Dividend Yield0.63%

Beta0.91

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2018, the company had approximately 17 million members in medical benefit plans, as well as approximately 6 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Beat the Market (BTM) Rank^™

2.4 Analyst's Opinion

Consensus Rating
Humana has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 13 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $405.94, Humana has a potential upside of 2.9% from its current price of $394.43.
Amount of Analyst Coverage
Humana has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Humana has received 788 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Humana has received 814 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Humana has received 50.81% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote “Outperform” if you believe HUM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
Humana is a leading dividend payer. It pays a dividend yield of 0.63%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Humana has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Humana is 13.99 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Humana will have a dividend payout ratio of 11.44 % next year. This indicates that Humana will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Humana insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,485,902.00 in company stock.
Percentage Held by Insiders
Only 0.42% of the stock of Humana is held by insiders.
Percentage Held by Institutions
93.22% of the stock of Humana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Humana are expected to grow by 17.79% in the coming year, from $18.55 to $21.85 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Humana is 20.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.42.
Price to Earnings Ratio vs. Sector
The P/E ratio of Humana is 20.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.03.
Price to Earnings Growth Ratio
Humana has a PEG Ratio of 1.72. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Humana has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.26 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Hospital & medical service plans

Sub-IndustryManaged Health Care

SectorMedical

Current SymbolNYSE:HUM

Previous Symbol

CUSIP44485910

CIK49071

Webwww.humana.com

Phone502-580-1000

Debt

Debt-to-Equity Ratio0.49

Current Ratio1.66

Quick Ratio1.66

Price-To-Earnings

Trailing P/E Ratio20.25

Forward P/E Ratio21.26

P/E Growth1.72

Sales & Book Value

Annual Sales$64.89 billion

Price / Sales0.80

Cash Flow$22.51 per share

Price / Cash Flow17.52

Book Value$93.45 per share

Price / Book4.22

Profitability

EPS (Most Recent Fiscal Year)$17.87

Net Income$2.71 billion

Net Margins3.86%

Return on Equity21.02%

Return on Assets8.26%

Miscellaneous

Employees46,000

Outstanding Shares132,210,000

Market Cap$52.15 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

Humana (NYSE:HUM) Frequently Asked Questions

How has Humana's stock been impacted by COVID-19 (Coronavirus)?

Humana's stock was trading at $328.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HUM stock has increased by 20.2% and is now trading at $394.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Humana?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Humana.

When is Humana's next earnings date?

Humana is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Humana.

How were Humana's earnings last quarter?

Humana Inc (NYSE:HUM) posted its earnings results on Wednesday, April, 29th. The insurance provider reported $5.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.84 by $0.56. The insurance provider had revenue of $18.94 billion for the quarter, compared to analyst estimates of $18.49 billion. Humana had a net margin of 3.86% and a return on equity of 21.02%. The business's revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.48 EPS. View Humana's earnings history.

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Thursday, April 23rd. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.625 per share on Friday, July 31st. This represents a $2.50 annualized dividend and a yield of 0.63%. The ex-dividend date is Monday, June 29th. View Humana's dividend history.

What guidance has Humana issued on next quarter's earnings?

Humana issued an update on its FY20 earnings guidance on Wednesday, April, 29th. The company provided earnings per share (EPS) guidance of $18.25-18.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $18.45.

What price target have analysts set for HUM?

18 equities research analysts have issued 12 month price objectives for Humana's stock. Their forecasts range from $290.00 to $500.00. On average, they expect Humana's stock price to reach $405.94 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price. View analysts' price targets for Humana.

Has Humana been receiving favorable news coverage?

News stories about HUM stock have trended extremely negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Humana earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the insurance provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutHumana.

Are investors shorting Humana?

Humana saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,010,000 shares, an increase of 9.8% from the March 31st total of 1,830,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.5% of the company's shares are sold short. View Humana's Current Options Chain.

Who are some of Humana's key competitors?

Some companies that are related to Humana include UnitedHealth Group (UNH), Anthem (ANTM), Cigna (CI), Centene (CNC), Molina Healthcare (MOH), Magellan Health (MGLN) and Triple-S Management (GTS). View all competitors.

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Visa (V), Walt Disney (DIS), Alibaba Group (BABA), Mastercard (MA), Boeing (BA), salesforce.com (CRM), JPMorgan Chase & Co. (JPM) and CVS Health (CVS).

Who are Humana's key executives?

Humana's management team includes the following people:

Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
Mr. Timothy S. Huval, Chief HR Officer (Age 53)
Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Who are Humana's major shareholders?

Humana's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.18%), Capital International Investors (6.32%), State Street Corp (4.40%), Capital World Investors (3.63%), Capital Research Global Investors (2.80%) and Wellington Management Group LLP (1.68%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James J /Ky Obrien, Jody L Bilney, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View institutional ownership trends for Humana.

Which major investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, BlackRock Inc., California Public Employees Retirement System, PointState Capital LP, Capital World Investors, Grantham Mayo Van Otterloo & Co. LLC, and Ruffer LLP. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, David A Jr/Ky Jones, Elizabeth D Bierbower, James J /Ky Obrien, Timothy Alan Wheatley, and Timothy S Huval. View insider buying and selling activity for Humana.

Which major investors are buying Humana stock?

HUM stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Jennison Associates LLC, Lone Pine Capital LLC, Janus Henderson Group PLC, Maverick Capital Ltd., Unigestion Holding SA, AJO LP, and AQR Capital Management LLC. View insider buying and selling activity for Humana.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $394.43.

How big of a company is Humana?

Humana has a market capitalization of $52.15 billion and generates $64.89 billion in revenue each year. The insurance provider earns $2.71 billion in net income (profit) each year or $17.87 on an earnings per share basis. Humana employs 46,000 workers across the globe.

What is Humana's official website?

The official website for Humana is www.humana.com.

How can I contact Humana?

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff